Dr. Duncan Eaves Berry, MD

Dr. Berry practices at Charlotte Eye Ear Nose & Throat Associates, PA in Concord, North Carolina.

Dr. Berry's NPI, 1326488560, was assigned on July 2, 2013. Dr. Berry graduated from Medical University of South Carolina College of Medicine in 2013. Dr. Berry holds North Carolina license 2017-00442.

Dr. Berry's primary practice is Charlotte Eye Ear Nose & Throat Associates, PA, at 645 Amalia NE St, Concord, NC 28025 in Cabarrus County. The practice phone is (704) 782-2166.

Dr. Berry's primary practice is Charlotte Eye Ear Nose & Throat Associates, PA in Concord, North Carolina. Dr. Berry is also affiliated with Novant Health Presbyterian Medical Center. The medical group on file is Charlotte Eye Ear Nose & Throat Associates (CEENTA). Dmand AI also links Dr. Berry to 1 more group practice or clinic, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Berry practices, 2 sites in all. Vendor and product names are available with a free account.

Ophthalmology is Dr. Berry's primary specialty in the NPI Registry, under taxonomy code 207W00000X. Dmand AI has Dr. Berry's licenses on file in 2 states: North Carolina and Georgia.

CMS data shows 23,765 Medicare services from Dr. Berry across 15 procedure codes in 2024, for 635 Medicare patients. Medicare paid $1,530,250 for them. Every service was in an office.

CMS counts 635 Medicare patients who saw Dr. Berry in 2024. The largest group is 75 to 84, with 245 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 6% are also on Medicaid. Their average risk score is 1.58, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Berry's median patient age at 71, with 58% women.

In 2024, Dr. Berry wrote 690 Medicare Part D claims for 198 patients. 62% of them were for generic drugs. CMS names the drug for 615 of them, across 11 drugs with 11 or more claims each, at $13,456 in total drug cost. In 2023, CMS named 494 claims across 12 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 94 out of 100 for Dr. Berry for performance year 2024, reported through an alternative payment model (APM). Dr. Berry accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links 20 papers to Dr. Berry, published from 2018 to 2022. 2019 was the busiest year, with 5. The most frequent topics are Biomarkers, Tumor, Biopsy, Fine-Needle and Fluorescein Angiography. Dr. Berry has published most often in Ophthalmol Retina. Dr. Berry's most frequent co-authors are Sharon Fekrat, MD, Prithvi Mruthyunjaya, MD and Amy C. Schefler, MD.

CMS Open Payments shows 25 general payments to Dr. Berry from 13 drug and device companies from 2016 to 2025. Travel and lodging make up the largest share, 53% of the total. Regeneron Pharmaceuticals, Inc. paid the most, $919.

Dr. Berry graduated from Medical University of South Carolina College of Medicine in 2013.